White Paper

Characterizing The Use Of External Controls For Augmenting Randomized Control Arms And Confirming Benefit

Source: Medidata AI
Cancer patient

Friends of Cancer Research (Friends) convened a working group to characterize methodological processes and to discuss the implementation and opportunities for formal regulatory use of external controls. This whitepaper describes several approaches to constructing an external control and also considers the use of hybrid designs that supplement or augment the control group in the randomized control trials (RCT) with data from an external population. This whitepaper further discusses statistical methodology to help address potential biases and improve the usefulness of the data as well as other adjustment methods that rely on patient summary data. In addition, we describe several scenarios where the use of external controls may be advantageous and practices that can help guide the implementation within a clinical study. A use case was prepared that characterizes the construction of an external control using clinical trial data in multiple myeloma to compare the treatment effect with a randomized control versus an external control and assesses the potential impact of unmeasured confounders. 

VIEW THE WHITE PAPER!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader